Arvinas (ARVN) Stock Forecast, Price Target & Predictions
ARVN Stock Forecast
Arvinas stock forecast is as follows: an average price target of $58.50 (represents a 216.56% upside from ARVN’s last price of $18.48) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
ARVN Price Target
ARVN Analyst Ratings
Buy
Arvinas Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 10, 2024 | Jeet Mukherjee | BTIG | $69.00 | $24.59 | 180.60% | 273.38% |
Nov 19, 2024 | Christopher Liu | Leerink Partners | $62.00 | $24.94 | 148.60% | 235.50% |
Oct 31, 2024 | Matthew Biegler | Oppenheimer | $40.00 | $27.66 | 44.61% | 116.45% |
Oct 21, 2024 | Bradley Canino | Stifel Nicolaus | $63.00 | $27.11 | 132.39% | 240.91% |
May 16, 2024 | Matthew Biegler | Oppenheimer | $70.00 | $32.11 | 118.00% | 278.79% |
Apr 12, 2024 | Andrew Fein | H.C. Wainwright | $87.00 | $37.26 | 133.49% | 370.78% |
Apr 11, 2024 | Bradley Canino | Stifel Nicolaus | $72.00 | $38.73 | 85.90% | 289.61% |
Dec 19, 2023 | Derek Archila | Wells Fargo | $63.00 | $37.87 | 66.36% | 240.91% |
Oct 23, 2023 | Robert Driscoll | Wedbush | $24.00 | $14.83 | 61.83% | 29.87% |
Jan 03, 2023 | Wells Fargo | $49.00 | $34.21 | 43.23% | 165.15% | |
Dec 05, 2022 | Citigroup | $72.00 | $41.39 | 73.96% | 289.61% | |
Nov 23, 2022 | Barclays | $70.00 | $40.70 | 71.99% | 278.79% | |
Nov 22, 2022 | Edward Tenthoff | Piper Sandler | $81.00 | $40.70 | 99.02% | 338.31% |
Nov 11, 2022 | Morgan Stanley | $57.00 | $45.98 | 23.97% | 208.44% | |
Feb 18, 2022 | Robert Driscoll | Wedbush | $98.00 | $69.02 | 41.99% | 430.30% |
Feb 09, 2022 | Derek Archila | Wells Fargo | $98.00 | $74.68 | 31.23% | 430.30% |
Sep 09, 2021 | Tazeen Ahmad | Bank of America Securities | $110.00 | $95.07 | 15.70% | 495.24% |
Aug 05, 2021 | Edward Tenthoff | Piper Sandler | $125.00 | $101.40 | 23.27% | 576.41% |
May 20, 2021 | Eliana Merle | UBS | $123.00 | $63.95 | 92.34% | 565.58% |
Arvinas Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 2 | 4 | 8 |
Avg Price Target | $65.50 | $58.50 | $65.75 |
Last Closing Price | $18.48 | $18.48 | $18.48 |
Upside/Downside | 254.44% | 216.56% | 255.79% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Dec 10, 2024 | BTIG | Buy | Initialise | |
Nov 19, 2024 | Leerink Partners | Outperform | Outperform | Hold |
Oct 31, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Sep 09, 2024 | Wedbush | Buy | Buy | Hold |
Jul 31, 2024 | Wells Fargo | Buy | Buy | Hold |
May 17, 2024 | Wells Fargo | Buy | Buy | Hold |
May 16, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Apr 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Dec 19, 2023 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
Dec 06, 2023 | Jefferies | Buy | Upgrade | |
Nov 20, 2023 | Guggenheim | Neutral | Buy | Upgrade |
Oct 24, 2023 | Barclays | Overweight | Overweight | Hold |
Oct 23, 2023 | Wedbush | Outperform | Upgrade | |
Aug 09, 2023 | Barclays | Overweight | Overweight | Hold |
May 08, 2023 | Credit Suisse | Buy | Buy | Hold |
Jan 12, 2023 | Guggenheim | Neutral | Downgrade | |
Jan 03, 2023 | Wells Fargo | Equal-Weight | Downgrade | |
Dec 05, 2022 | Citigroup | Buy | Buy | Hold |
Nov 23, 2022 | Barclays | Overweight | Overweight | Hold |
Nov 22, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Nov 11, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Apr 26, 2022 | Zacks Investment Research | Hold | Downgrade | |
Feb 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Arvinas Financial Forecast
Arvinas Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $-43.10M | $34.60M | $54.50M | $32.50M | $38.00M | $30.30M | $31.30M | $24.20M | $25.63M | $9.28M | $5.54M | $5.54M | $2.22M | $7.60M | $5.75M | $6.24M | $4.89M | $30.05M | $4.02M | $4.02M | $3.38M |
Avg Forecast | $79.86M | $58.98M | $36.41M | $36.51M | $62.00M | $60.56M | $33.27M | $32.94M | $48.33M | $39.45M | $30.94M | $27.91M | $35.72M | $34.70M | $24.75M | $25.45M | $14.14M | $196.39M | $5.60M | $3.68M | $6.89M | $5.22M | $5.36M | $4.44M | $5.34M | $4.44M | $3.69M | $3.44M | $7.50M |
High Forecast | $120.92M | $89.31M | $55.14M | $55.29M | $120.62M | $91.70M | $33.27M | $32.94M | $69.63M | $39.52M | $46.85M | $42.26M | $54.09M | $34.70M | $24.75M | $25.45M | $14.14M | $196.39M | $5.60M | $3.68M | $6.89M | $5.22M | $5.36M | $4.44M | $5.34M | $4.44M | $3.69M | $3.44M | $9.00M |
Low Forecast | $52.79M | $38.99M | $24.07M | $24.14M | $29.96M | $40.03M | $33.27M | $32.94M | $37.27M | $39.39M | $20.45M | $18.45M | $23.61M | $34.70M | $24.75M | $25.45M | $14.14M | $196.39M | $5.60M | $3.68M | $6.89M | $5.22M | $5.36M | $4.44M | $5.34M | $4.44M | $3.69M | $3.44M | $6.00M |
# Analysts | 3 | 3 | 3 | 5 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
Surprise % | - | - | - | - | - | - | - | - | -0.89% | 0.88% | 1.76% | 1.16% | 1.06% | 0.87% | 1.26% | 0.95% | 1.81% | 0.05% | 0.99% | 1.51% | 0.32% | 1.45% | 1.07% | 1.40% | 0.92% | 6.78% | 1.09% | 1.17% | 0.45% |
Forecast
Arvinas EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
EBITDA | - | - | - | - | - | - | - | - | $-165.30M | $-73.90M | $-74.60M | $-87.70M | $-75.40M | $-65.10M | $-66.40M | $-57.90M | $-52.37M | $-45.23M | $-48.80M | $-39.49M | $-40.24M | $-29.71M | $-24.35M | $-20.94M | $-20.31M | $-17.04M | $-16.65M | $-13.95M | $-13.18M |
Avg Forecast | $-79.86M | $-58.98M | $-36.41M | $-36.51M | $-62.00M | $-60.56M | $-33.27M | $-43.84M | $-48.33M | $-39.45M | $-30.94M | $-39.86M | $-35.95M | $-34.70M | $-24.75M | $-36.23M | $-14.14M | $-196.39M | $-5.60M | $-38.53M | $-6.89M | $-5.22M | $-5.36M | $-22.33M | $-5.34M | $-4.44M | $-3.69M | $-13.95M | $-29.31M |
High Forecast | $-52.79M | $-38.99M | $-24.07M | $-24.14M | $-29.96M | $-40.03M | $-33.27M | $-35.07M | $-37.27M | $-39.39M | $-20.45M | $-31.89M | $-28.76M | $-34.70M | $-24.75M | $-28.99M | $-14.14M | $-196.39M | $-5.60M | $-30.83M | $-6.89M | $-5.22M | $-5.36M | $-17.86M | $-5.34M | $-4.44M | $-3.69M | $-11.16M | $-23.44M |
Low Forecast | $-120.92M | $-89.31M | $-55.14M | $-55.29M | $-120.62M | $-91.70M | $-33.27M | $-52.61M | $-69.63M | $-39.52M | $-46.85M | $-47.83M | $-43.14M | $-34.70M | $-24.75M | $-43.48M | $-14.14M | $-196.39M | $-5.60M | $-46.24M | $-6.89M | $-5.22M | $-5.36M | $-26.80M | $-5.34M | $-4.44M | $-3.69M | $-16.75M | $-35.17M |
Surprise % | - | - | - | - | - | - | - | - | 3.42% | 1.87% | 2.41% | 2.20% | 2.10% | 1.88% | 2.68% | 1.60% | 3.70% | 0.23% | 8.72% | 1.03% | 5.84% | 5.69% | 4.55% | 0.94% | 3.80% | 3.84% | 4.51% | 1.00% | 0.45% |
Forecast
Arvinas Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
Net Income | - | - | - | - | - | - | - | - | $-154.80M | $-64.00M | $-66.60M | $-80.80M | $-79.90M | $-66.20M | $-70.00M | $-63.40M | $-53.06M | $-46.75M | $-50.29M | $-40.96M | $-41.55M | $-30.82M | $-25.23M | $-21.74M | $-21.05M | $-17.68M | $-17.16M | $-14.40M | $-13.39M |
Avg Forecast | $-82.06M | $-76.16M | $-98.24M | $-92.82M | $-69.14M | $-60.76M | $-78.19M | $-49.99M | $-85.71M | $-114.12M | $-118.95M | $-45.45M | $-36.38M | $-83.72M | $-78.74M | $-41.32M | $-56.61M | $152.57M | $-62.05M | $-39.97M | $-54.49M | $-48.95M | $-42.65M | $-23.19M | $-38.94M | $-33.30M | $-28.87M | $-14.40M | $-29.76M |
High Forecast | $-45.90M | $-42.60M | $-54.96M | $-64.10M | $-14.22M | $-33.99M | $-43.74M | $-39.99M | $-48.33M | $-63.84M | $-66.54M | $-36.36M | $-29.10M | $-83.72M | $-78.74M | $-33.05M | $-56.61M | $152.57M | $-62.05M | $-31.97M | $-54.49M | $-48.95M | $-42.65M | $-18.55M | $-38.94M | $-33.30M | $-28.87M | $-11.52M | $-23.81M |
Low Forecast | $-136.92M | $-127.07M | $-163.93M | $-109.51M | $-120.83M | $-101.38M | $-130.46M | $-59.99M | $-128.25M | $-190.42M | $-198.48M | $-54.54M | $-43.65M | $-83.72M | $-78.74M | $-49.58M | $-56.61M | $152.57M | $-62.05M | $-47.96M | $-54.49M | $-48.95M | $-42.65M | $-27.83M | $-38.94M | $-33.30M | $-28.87M | $-17.29M | $-35.71M |
Surprise % | - | - | - | - | - | - | - | - | 1.81% | 0.56% | 0.56% | 1.78% | 2.20% | 0.79% | 0.89% | 1.53% | 0.94% | -0.31% | 0.81% | 1.03% | 0.76% | 0.63% | 0.59% | 0.94% | 0.54% | 0.53% | 0.59% | 1.00% | 0.45% |
Forecast
Arvinas SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
SG&A | - | - | - | - | - | - | - | - | $27.00M | $22.60M | $25.70M | $24.90M | $15.10M | $20.00M | $24.30M | $20.20M | $18.26M | $16.01M | $14.41M | $12.32M | $12.23M | $9.33M | $8.82M | $7.93M | $7.27M | $7.96M | $6.44M | $5.64M | $4.28M |
Avg Forecast | $89.36M | $66.00M | $40.75M | $40.86M | $69.38M | $67.76M | $37.23M | $15.93M | $54.08M | $44.15M | $34.62M | $14.48M | $12.53M | $38.24M | $27.27M | $13.16M | $15.58M | $216.40M | $6.17M | $4.06M | $7.59M | $5.75M | $5.90M | $4.90M | $5.89M | $4.89M | $4.06M | $3.79M | $8.27M |
High Forecast | $135.31M | $99.94M | $61.70M | $61.87M | $134.97M | $102.61M | $37.23M | $19.11M | $77.91M | $44.22M | $52.42M | $17.38M | $15.04M | $38.24M | $27.27M | $15.80M | $15.58M | $216.40M | $6.17M | $4.06M | $7.59M | $5.75M | $5.90M | $4.90M | $5.89M | $4.89M | $4.06M | $3.79M | $9.92M |
Low Forecast | $59.07M | $43.63M | $26.94M | $27.01M | $33.52M | $44.80M | $37.23M | $12.74M | $41.70M | $44.07M | $22.89M | $11.58M | $10.03M | $38.24M | $27.27M | $10.53M | $15.58M | $216.40M | $6.17M | $4.06M | $7.59M | $5.75M | $5.90M | $4.90M | $5.89M | $4.89M | $4.06M | $3.79M | $6.61M |
Surprise % | - | - | - | - | - | - | - | - | 0.50% | 0.51% | 0.74% | 1.72% | 1.20% | 0.52% | 0.89% | 1.53% | 1.17% | 0.07% | 2.34% | 3.04% | 1.61% | 1.62% | 1.49% | 1.62% | 1.23% | 1.63% | 1.59% | 1.49% | 0.52% |
Forecast
Arvinas EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 5 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 |
EPS | - | - | - | - | - | - | - | - | $-2.53 | $-1.18 | $-1.25 | $-1.52 | $-1.50 | $-1.24 | $-1.32 | $-1.20 | $-1.00 | $-0.94 | $-1.03 | $-0.84 | $-0.99 | $-0.79 | $-0.65 | $-0.56 | $-0.56 | $-0.54 | $-0.55 | $-0.46 | $-6.66 |
Avg Forecast | $-1.14 | $-1.06 | $-1.36 | $-1.29 | $-0.96 | $-0.84 | $-1.08 | $-1.42 | $-1.19 | $-1.58 | $-1.65 | $-1.54 | $-1.17 | $-1.16 | $-1.10 | $-0.93 | $-0.79 | $2.12 | $-0.86 | $-0.83 | $-0.76 | $-0.68 | $-0.59 | $-0.57 | $-0.54 | $-0.46 | $-0.40 | $-0.46 | $-3.31 |
High Forecast | $-0.64 | $-0.59 | $-0.76 | $-0.89 | $-0.20 | $-0.47 | $-0.61 | $-0.79 | $-0.67 | $-0.89 | $-0.92 | $-0.86 | $-0.66 | $-1.16 | $-1.10 | $-0.93 | $-0.79 | $2.12 | $-0.86 | $-0.83 | $-0.76 | $-0.68 | $-0.59 | $-0.57 | $-0.54 | $-0.46 | $-0.40 | $-0.46 | $-2.65 |
Low Forecast | $-1.90 | $-1.76 | $-2.27 | $-1.52 | $-1.68 | $-1.41 | $-1.81 | $-2.37 | $-1.78 | $-2.64 | $-2.75 | $-2.57 | $-1.96 | $-1.16 | $-1.10 | $-0.93 | $-0.79 | $2.12 | $-0.86 | $-0.83 | $-0.76 | $-0.68 | $-0.59 | $-0.57 | $-0.54 | $-0.46 | $-0.40 | $-0.46 | $-3.97 |
Surprise % | - | - | - | - | - | - | - | - | 2.13% | 0.75% | 0.76% | 0.99% | 1.28% | 1.06% | 1.21% | 1.29% | 1.27% | -0.44% | 1.19% | 1.01% | 1.31% | 1.16% | 1.10% | 0.99% | 1.03% | 1.17% | 1.37% | 0.99% | 2.01% |
Forecast
Arvinas Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
KURA | Kura Oncology | $9.74 | $23.33 | 139.53% | Buy |
STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
RARE | Ultragenyx Pharmaceutical | $44.95 | $90.00 | 100.22% | Buy |
NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |
CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |